2 completed, 2 not yet recruiting, 1 active not recruiting, 1 enrolling by invitation. 4 Not applicable, 1 Early Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Not yet recruiting 2, Completed 1, Enrolling by invitation 1 |
| Early Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Immunosuppresion: new trials by email Literature Review of Immunosuppresion trials Research Report on Immunosuppresion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT) Prospera Immunosuppression Optimization - Kidney Transplant, Immunosuppresion | Not applicable | Not yet recruiting | Natera, Inc. | 750 | 2026-07-01 | 2026-07-22 |
| Tolerance Through Mixed Chimerism (Sip-Tego) Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart) - Kidney Failure, Transplant Recipient (Kidney) | Early Phase 1 | Active not recruiting | Tatsuo Kawai, MD, PhD | 12 | 2025-05-31 | 2026-09-25 |
| Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant (PART) Prevention of Allosensitization - Kidney Transplant, Kidney Transplant Failure | Not applicable | Not yet recruiting | University of British Columbia | 96 | 2025-01-01 | 2025-01-31 |
| Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia Dexamethasone, Tocilizumab, Anakinra - Sepsis, Neuroinflammatory Response | Phase 4 | Unknown | Radboud University Medical Center | 52 | 2024-10-24 | 2025-04-04 |
| Improving Shingrix Vaccination Among US Veterans Receiving Immunosuppression Access to Shingrix dashboard - Immunosuppresion | Not applicable | Enrolling by invitation | University of California, San Francisco | 130 | 2024-09-16 | 2025-04-06 |
| Determining the Fingerprint of Endotoxin Tolerance Endotoxin (E. coli O:113, Reference Endotoxin) - Endotoxemia, Sepsis | Not applicable | Completed | Radboud University Medical Center | 110 | 2019-05-27 | 2025-02-07 |
| Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management (MYOPED) support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation - Myocarditis, Ventricular Arrhythmia | Recruiting | Scientific Institute San Raffaele | 20 | 2013-01-01 | 2024-09-19 | |
| Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine - Immunosuppresion, Thrombocytopenia | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 136 | 2005-11-28 | 2017-06-08 |
Autoimmune Diseases (2) · Endotoxemia (2) · Sepsis (2) · Anemia, Aplastic (1) · Arrhythmias, Cardiac (1) · Cardiomyopathies (1) · Genetic Predisposition to Disease (1) · Myocarditis (1) · Neuroinflammatory Diseases (1) · Neutropenia (1) · Pancytopenia (1) · Renal Insufficiency (1) · Thrombocytopenia (1)
Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Bacteremia (2) · Immune System Diseases (2) · Infections (2) · Inflammation (2) · Systemic Inflammatory Response Syndrome (2) · Toxemia (2) · Agranulocytosis (1) · Anemia (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Bone Marrow Failure Disorders (1) · Cardiovascular Diseases (1) · Cytopenia (1)
Antilymphocyte Serum (2) · Endotoxins (2) · Lipopolysaccharides (2) · Alemtuzumab (1) · Cyclophosphamide (1) · Cyclosporine (1) · Dexamethasone (1) · Equipment and Supplies (1) · Interleukin 1 Receptor Antagonist Protein (1) · Rituximab (1) · Sodium Chloride (1) · Transplantation Conditioning (1) · siplizumab (1) · tocilizumab (1)
Radboud University Medical Center (2) · Natera, Inc. (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Scientific Institute San Raffaele (1) · Tatsuo Kawai, MD, PhD (1) · University of British Columbia (1) · University of California, San Francisco (1)
United States (3) · Netherlands (2) · Canada (1) · Italy (1)
Danielle M Townsley, M.D. (1) · Gabriela Schmajuk, MD MS (1) · Paolo Della Bella, MD (1) · Tatsuo Kawai, MD PhD (1)
PMID 27658437, PMID 29674506, PMID 29958797, PMID 34724566
2023 (1), I50HX003266 (1)